147 related articles for article (PubMed ID: 12537516)
21. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
22. A lack of pharmacokinetic interaction between ranitidine and piroxicam.
Dixon JS; Lacey LF; Pickup ME; Langley SJ; Page MC
Eur J Clin Pharmacol; 1990; 39(6):583-6. PubMed ID: 1982764
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis.
James LP; Stowe CD; Farrar HC; Menendez AA; Argao EA
J Clin Pharmacol; 1999 Dec; 39(12):1242-7. PubMed ID: 10586389
[TBL] [Abstract][Full Text] [Related]
24. A pharmacokinetic model for multiple sites discontinuous gastrointestinal absorption.
Plusquellec Y; Efthymiopoulos C; Duthil P; Houin G
Med Eng Phys; 1999 Oct; 21(8):525-32. PubMed ID: 10672785
[TBL] [Abstract][Full Text] [Related]
25. In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption.
Deng J; Jhandey A; Zhu X; Yang Z; Yik KFP; Zuo Z; Lam TN
PLoS One; 2018; 13(8):e0203361. PubMed ID: 30169515
[TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal transit and distribution of ranitidine in the rat.
Suttle AB; Brouwer KL
Pharm Res; 1995 Sep; 12(9):1316-22. PubMed ID: 8570528
[TBL] [Abstract][Full Text] [Related]
27. Comparative bioavailability of two tablet formulations of ranitidine hydrochloride in healthy volunteers.
Bawazir SA; Gouda MW; El-Sayed YM; Al-Khamis KI; Al-Yamani MJ; Niazy EM; Al-Rashood KA
Int J Clin Pharmacol Ther; 1998 May; 36(5):270-4. PubMed ID: 9629991
[TBL] [Abstract][Full Text] [Related]
28. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride.
Kortejärvi H; Yliperttula M; Dressman JB; Junginger HE; Midha KK; Shah VP; Barends DM
J Pharm Sci; 2005 Aug; 94(8):1617-25. PubMed ID: 15959881
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic-pharmacodynamic modeling of oral ranitidine: implications in efficacy and safety.
Franco C; Flores-Murrieta FJ; Castañeda-Hernández G
Proc West Pharmacol Soc; 1997; 40():107-9. PubMed ID: 9436228
[No Abstract] [Full Text] [Related]
30. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.
Prémaud A; Debord J; Rousseau A; Le Meur Y; Toupance O; Lebranchu Y; Hoizey G; Le Guellec C; Marquet P
Clin Pharmacokinet; 2005; 44(8):837-47. PubMed ID: 16029068
[TBL] [Abstract][Full Text] [Related]
31. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
Collett A; Higgs NB; Sims E; Rowland M; Warhurst G
J Pharmacol Exp Ther; 1999 Jan; 288(1):171-8. PubMed ID: 9862768
[TBL] [Abstract][Full Text] [Related]
32. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
33. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine.
Williams MF; Dukes GE; Heizer W; Han YH; Hermann DJ; Lampkin T; Hak LJ
Pharm Res; 1992 Sep; 9(9):1190-4. PubMed ID: 1409403
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of ranitidine after partial gastrectomy in dogs.
Makil O; Kaltenbach ML; Limberg J; Harrison D; Hocking MP; Derendorf H
J Pharm Sci; 1991 Nov; 80(11):1034-6. PubMed ID: 1815053
[TBL] [Abstract][Full Text] [Related]
35. Modeling of trough plasma bismuth concentrations.
Bennett JE; Wakefield JC; Lacey LF
J Pharmacokinet Biopharm; 1997 Feb; 25(1):79-106. PubMed ID: 9353695
[TBL] [Abstract][Full Text] [Related]
36. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
Zhang T; Heimbach T; Lin W; Zhang J; He H
J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of oral ranitidine in Mexicans.
Castañeda-Hernández G; Flores-Murrieta FJ; Granados-Soto V; Herrera-Abarca A; Pérez-Urizar J; Herrera JE; Hong E
Arch Med Res; 1996; 27(3):349-52. PubMed ID: 8854394
[TBL] [Abstract][Full Text] [Related]
38. The effect of H2-antagonists on the absorption of bupropion in rats.
al-Khamis KI; Kaka JS; Tanira MO
Res Commun Chem Pathol Pharmacol; 1988 Feb; 59(2):279-82. PubMed ID: 2895943
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment.
Koch KM; Liu M; Davis IM; Shaw S; Yin Y
Eur J Clin Pharmacol; 1997; 52(3):229-34. PubMed ID: 9218931
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and bioavailability of ranitidine in humans.
Miller R
J Pharm Sci; 1984 Oct; 73(10):1376-9. PubMed ID: 6094785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
